Completed PHASE3 INTERVENTIONAL 2-arm NCT00955799

Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus

A Randomized, Double-Blind, Placebo-Controlled, Clinical Evaluation of the Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus

Sponsor: Merz Pharmaceuticals GmbH

Conditions Subjective Tinnitus

Interventions Neramexane mesylate Placebo

Updated 8 times since 2017 Last updated: Nov 27, 2012 Started: Sep 30, 2009 Primary completion: May 31, 2011 Completion: Jun 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00955799, this PHASE3 trial focuses on Subjective Tinnitus and remains completed. Sponsored by Merz Pharmaceuticals GmbH, it has been updated 8 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Apr 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Apr 2022 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merz Pharmaceuticals GmbH

Data source: Merz Pharmaceuticals GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aguascalientes, Mexico , Austin, United States , Belo Horizonte, Brazil , Berlin, Germany , Bloomfield, United States , Boynton Beach, United States , Braunschweig, Germany , Buffalo, United States , Burbank, United States , Cary, United States and 58 more locations